Monte Rosa Therapeutics, Inc. Share Price
NASDAQ: GLUE | Small CapMonte Rosa Therapeutics, Inc. Stock Performance
Open $16.09 | Prev. Close $15.71 | Circuit Range N/A |
Day Range $15.73 - $16.12 | Year Range $4.14 - $25.75 | Volume 59,674 |
Average Traded $15.94 |
Monte Rosa Therapeutics, Inc. Share Price Today
As of 10 August 2026, Monte Rosa Therapeutics, Inc.'s share price is $15.89. The stock opened at $16.09, compared to its previous close of $15.71. During today's trading session, Monte Rosa Therapeutics, Inc.'s share price traded between $15.73 and $16.12, with an average price of $15.93. Over the past 52 weeks, the stock has recorded a high of $25.75 and a low of $4.14. In terms of performance, Monte Rosa Therapeutics, Inc.'s share price has declined by 10.50% over the last six months and is up 232.53% on a year-on-year basis.
Monte Rosa Therapeutics, Inc. Share Price Chart
Monte Rosa Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.32B | PE Ratio (TTM) -34.55 | Dividend Yield N/A |
EPS (TTM) $-0.46 | Revenue (TTM) $123.67M | Return On Equity (TTM) -16.57% |
Profit Margin -31.23% | Debt to Equity 0.28 | Quarterly Earnings Growth YoY -13.50% |
Monte Rosa Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Monte Rosa Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $16.73 | $15.89 | -3.84% |
Jul 2026 | $24.40 | $16.53 | -31.82% |
Jun 2026 | $19.73 | $24.25 | +23.01% |
May 2026 | $18.98 | $19.71 | +2.92% |
Apr 2026 | $16.89 | $19.15 | +16.48% |
Mar 2026 | $17.44 | $16.44 | -7.43% |
Feb 2026 | $20.65 | $17.76 | -13.47% |
Jan 2026 | $15.59 | $20.52 | +30.90% |
Dec 2025 | $15.91 | $15.68 | -3.23% |
Nov 2025 | $12.88 | $16.20 | +26.00% |
Oct 2025 | $7.44 | $12.86 | +73.78% |
Sep 2025 | $4.83 | $7.40 | +54.81% |
GLUE Share Price FAQs
What is Monte Rosa Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Monte Rosa Therapeutics, Inc. stock?
What is GLUE's market capitalisation today?
What is GLUE's net income for the last quarter?
What is the 5 year returns of GLUE?
What is the high & low stock price of GLUE today?
Can I buy GLUE shares in India?